Stefan Hendriks

Stefan Hendriks was appointed Global Head of Biopharmaceuticals at Sandoz in June 2018 and is part of the Sandoz Executive Committee. In this role, Stefan leads the organization that is responsible for the development and commercialization of biopharmaceuticals, including biosimilars. Sandoz has eight biosimilars approved in total, and under Stefan’s guidance, has launched three biosimilars in 2018 and continues to invest and expand the leading portfolio including into underserved therapy areas such as insulins.

Stefan brings considerable experience in launch excellence and team leadership as well as brand and franchise management with over 20 years of serving in the pharmaceutical industry. He believes in unlocking the potential of each individual by focusing on a growth mindset and creating an environment that is collaborative, curious and patient- and customer-centric.

Prior to joining Sandoz Stefan worked at Bristol-Myers Squibb (BMS) where he held numerous country, regional and global roles across sales, marketing, and general management for 15 years, and previously also worked for AstraZeneca. He has deep therapeutic area experience spanning immunology, oncology, endocrinology, virology, cardiovascular, and respiratory among others.